Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure...
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health...
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in...
Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today...
TAMPA, FL / ACCESS Newswire / November 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader...
Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year Sofinnova Capital XI is actively investing in early-stage...
Local Clinic Offers Newly Approved Monotherapy Option for Treatment-Resistant Depression - No Daily Antidepressant Required SAN LUIS OBISPO, CA /...
"The federal hemp crackdown has created long overdue pharmaceutical clarity. MMJ is now the company advancing a fully compliant cannabinoid...
DALLAS, Nov. 16, 2025 /PRNewswire/ -- Fotona, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental...
KNOXVILLE, Tenn., Nov. 15, 2025 (GLOBE NEWSWIRE) -- Sapphire RX advances digital health accessibility with an innovative telehealth model that...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE...
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular...
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE)...
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly...
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA...
NORTHVALE, NJ / ACCESS Newswire / November 14, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer...
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 /...
~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to...
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company...
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -- Dermata plans to launch...